{"id":207029,"name":"HOMOLOGY MEDICINES","slug":"homology-medicines","state":"MA","country":"United States of America","description":"Rare Disease research & cures","totalSpending":150000,"filings":9,"yearlySpending":[{"year":2020,"income":30000},{"year":2021,"income":80000},{"year":2022,"income":40000}],"issues":["HCR","MED"],"firms":["BURRELL INTERNATIONAL GROUP LLC"],"lobbyists":["DEBORAH BURRELL"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Rare Disease Research and cures through gene editing and gene therapy.","Drug pricing and gene therapy, generally;\nH.R. 4393 - Advancing Access to Precision Medicine;\nH.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act;\nH.R. 8045 - Genome Editing Threat Ass","Drug pricing, gene therapy, and rare disease funding generally;\nH.R. 4393 - Advancing Access to Precision Medicine;\nH.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act;\nH.R. 8045 - Gen","Drug pricing, gene therapy, and rare disease funding generally;\nAdvancing Access to Precision Medicine;\nNewborn Screening Saves Lives Reauthorization Act;\nGenome Editing Threat Assessment Act;\nMedical","Drug pricing, gene therapy, and rare disease funding generally;\nAdvancing Access to Precision Medicine;\nNewborn Screening Saves Lives Reauthorization Act;\nGenome Editing Threat Assessment Act;\nMedical"],"years":[2020,2021,2022]}